WO2003018581A1 - Derive de 1,2-dihydro-2-oxo-1,8-naphthyridine - Google Patents
Derive de 1,2-dihydro-2-oxo-1,8-naphthyridine Download PDFInfo
- Publication number
- WO2003018581A1 WO2003018581A1 PCT/JP2002/008266 JP0208266W WO03018581A1 WO 2003018581 A1 WO2003018581 A1 WO 2003018581A1 JP 0208266 W JP0208266 W JP 0208266W WO 03018581 A1 WO03018581 A1 WO 03018581A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxo
- dihydro
- hydroxy
- compound according
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to 1,2-dihydro-12-oxo-1, which has an inhibitory action on Acinole-1 CoA: cholesterol monoalesinoletransferase (ACAT) and is useful as a therapeutic agent for hyperlipidemia and arteriosclerosis. It relates to hydrates of 1,8-naphthyridine derivatives. Background art
- Acinolay CoA N- [1-butyl-4-1 [3-] is a compound that has cholesterol acyltransferase (ACAT) inhibitory activity and is useful as a therapeutic agent for hyperlipidemia and Z or atherosclerosis.
- ACAT cholesterol acyltransferase
- a colorless amorphous form of 'rea' hydrochloride is disclosed in WO 0 OZO 9505. Disclosure of the invention
- An object of the present invention is to provide an ACAT inhibitory activity, which is useful as a therapeutic agent for hyperlipidemia and an arteriosclerosis agent.
- [ ⁇ - [1-butyl-14-1] [3- [3- (hydroxy) propoxy] feninole ] - 1, 2-dihydro-one 2- Okiso one 1, 8-naphthyridine one 3 le] -N; - (2, 6 Jiisopuropiru one 4-aminophenyl) Urea or a drug histological acceptable salt thereof, stable To provide a hydrate.
- An acyl CoA cholesterol acyl transferase (ACAT) inhibitor comprising the compound according to any one of [1] to [3] as an active ingredient.
- ACAT cholesterol acyl transferase
- a therapeutic agent for hyperlipidemia or arteriosclerosis comprising as an active ingredient the compound according to any one of [1] to [3].
- the value of the diffraction angle (20) in the powder X-ray diffraction of the crystal in the present specification represents a standard accuracy and is about ⁇ 0.1 degrees.
- one N '-( 2, 6-diisopropynolele 4-aminophenol) Perea hydrochloride is WO 00/095 It can be produced by the method described in Japanese Patent Publication No. 05 or a method analogous thereto. The monohydrate can be produced by keeping the hydrochloride in a water-containing hydrophilic solvent at a temperature of o ° C to the boiling point of the solvent. Further, it can also be produced by recrystallization with a water-containing hydrophilic solvent.
- hydrophilic solvent examples include alcohols such as methanol, ethanol, and isopropanol. Preferred hydrophilic solvents include methanol.
- the water content of the hydrophilic solvent is 0.5% (v / v) to 50% (v / v), more preferably 1% (v / v) to 20% (v / v).
- a liquid form such as a suspension can be administered as an injection, and a buffer, a solubilizing agent, an isotonic agent, and the like can be added as necessary. It can also be administered rectally in the form of suppositories.
- Such a dosage form can be produced according to a general method by mixing an active ingredient with a usual carrier, excipient, binder, stabilizer and the like.
- the dose and frequency of administration of the compound of the present invention vary depending on symptoms, age, body weight, dosage form, and the like.In general, in the case of oral administration, it is about 1 to 50 Omg per adult per day. It can be administered in 2 to 4 divided doses.
- FIG. 1 shows N- [1-butyl-1- [3- [3- (hydroxy) propoxy] pheninole] -1,2-dihydro-2-oxo-1,8 produced in Example 1.
- the horizontal axis represents the diffraction angle (2 [°] (degrees)
- the vertical axis represents the intensity [cps] (count per second).
- N- [1-butynole-1 4- [3- [3- (hydroxy) propoxy] phenyl]-1,2-dihydroxy_2-oxo-1,8-naphthyridin-3-inole] _N one (2, A suspension of 6-diisopropyl-14-aminophenyl) peria hydrochloride (125 g) amorphous solid in methanol (375 ml) was heated and stirred at about 60 ° C. to dissolve the solid. Water (3.7tnl) was added, and the mixture was stirred for 15 minutes and filtered while hot. The filtrate was stirred at 40 ° C to 50 ° C for about 2 hours and then allowed to cool. After stirring at room temperature for 14 hours, the mixture was stirred under ice cooling for 2 hours, and the precipitated crystals were collected by filtration to give the title compound as colorless crystals (87.5 g).
- the powder X-ray diffraction pattern was measured using RINT250V manufactured by Rigaku Corporation and using 1.541 A of CU-KQ;
- the diffraction angle (2 ⁇ ) and the relative intensity of the main peak in the powder X-ray diffraction pattern of the crystalline compound of the title are as shown in Table 1, and the diffraction pattern is as shown in FIG. table 1
- the hydrate of the present invention has much better stability than amorphous, it is less susceptible to degradation and content reduction during formulation and storage when used as pharmaceuticals, and more suitable pharmaceuticals Can be used as
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002456349A CA2456349A1 (en) | 2001-08-23 | 2002-08-14 | 1,2-dihydro-2-oxo-1,8-naphthyridine derivative |
JP2003523242A JP3787139B2 (ja) | 2001-08-23 | 2002-08-14 | 1,2−ジヒドロ−2−オキソ−1,8−ナフチリジン誘導体 |
NZ531073A NZ531073A (en) | 2001-08-23 | 2002-08-14 | 1,2-dihydro-2-oxo-1,8-naphthyridine derivative |
EP02760629A EP1420017A4 (en) | 2001-08-23 | 2002-08-14 | 1,2 DIHYDRO 2 OXO 1,8-NAPHTHYRIDINE DERIVATIVE |
US10/474,725 US7067528B2 (en) | 2001-08-23 | 2002-08-14 | 1, 2-dihydro-2-oxo-1, 8-naphthyridine derivative |
KR10-2004-7002489A KR20040036724A (ko) | 2001-08-23 | 2002-08-14 | 1,2-디히드로-2-옥소-1,8-나프티리딘 유도체 |
AU2002327093A AU2002327093B2 (en) | 2001-08-23 | 2002-08-14 | 1,2-dihydro-2-oxo-1,8-naphthyridine derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-252673 | 2001-08-23 | ||
JP2001252673 | 2001-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003018581A1 true WO2003018581A1 (fr) | 2003-03-06 |
Family
ID=19081111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/008266 WO2003018581A1 (fr) | 2001-08-23 | 2002-08-14 | Derive de 1,2-dihydro-2-oxo-1,8-naphthyridine |
Country Status (9)
Country | Link |
---|---|
US (1) | US7067528B2 (ja) |
EP (1) | EP1420017A4 (ja) |
JP (1) | JP3787139B2 (ja) |
KR (1) | KR20040036724A (ja) |
CN (1) | CN1266150C (ja) |
AU (1) | AU2002327093B2 (ja) |
CA (1) | CA2456349A1 (ja) |
NZ (1) | NZ531073A (ja) |
WO (1) | WO2003018581A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006011551A1 (ja) * | 2004-07-28 | 2006-02-02 | Sankyo Company Limited | 抗動脈硬化作用を有する医薬組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1913892A (zh) * | 2003-12-17 | 2007-02-14 | 大日本住友制药株式会社 | 药物组合物及联合药物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1104763A1 (en) * | 1998-08-11 | 2001-06-06 | Sumitomo Pharmaceuticals Company, Limited | Naphthyridine derivatives |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843957A (en) | 1995-05-19 | 1998-12-01 | Sumitomo Pharmaceuticals Company, Ltd. | Naphthyridine derivatives |
KR100399798B1 (ko) | 1995-05-31 | 2004-05-31 | 스미또모 세이야꾸 가부시키가이샤 | 신규나프티리딘유도체 |
JP2889864B2 (ja) * | 1996-02-28 | 1999-05-10 | 住友製薬株式会社 | 結晶態のビタミンd誘導体 |
JPH1053576A (ja) * | 1996-06-07 | 1998-02-24 | Eisai Co Ltd | 塩酸ドネペジルの多形結晶およびその製造法 |
CN1245500A (zh) | 1996-11-26 | 2000-02-23 | 住友制药株式会社 | 新型萘啶衍生物 |
JP3317649B2 (ja) * | 1997-01-13 | 2002-08-26 | 日本ワイスレダリー株式会社 | 結晶形態のカルバペネム化合物 |
EP1086948A4 (en) | 1998-02-25 | 2004-03-10 | Sumitomo Pharma | PYRIDONE DERIVATIVES AND THEIR MANUFACTURING PROCESS |
JPH11269194A (ja) * | 1998-03-19 | 1999-10-05 | Nissin Food Prod Co Ltd | パラトルオイルグルコシルジフルコルトロンの結晶化方法 |
JP2000212168A (ja) * | 1999-01-22 | 2000-08-02 | Yamanouchi Pharmaceut Co Ltd | ヘキサヒドロ―1,4―ジアゼピン誘導体塩水和物の新規結晶 |
-
2002
- 2002-08-14 JP JP2003523242A patent/JP3787139B2/ja not_active Expired - Fee Related
- 2002-08-14 AU AU2002327093A patent/AU2002327093B2/en not_active Ceased
- 2002-08-14 KR KR10-2004-7002489A patent/KR20040036724A/ko not_active Application Discontinuation
- 2002-08-14 EP EP02760629A patent/EP1420017A4/en not_active Withdrawn
- 2002-08-14 WO PCT/JP2002/008266 patent/WO2003018581A1/ja active IP Right Grant
- 2002-08-14 US US10/474,725 patent/US7067528B2/en not_active Expired - Fee Related
- 2002-08-14 NZ NZ531073A patent/NZ531073A/en unknown
- 2002-08-14 CN CNB028164431A patent/CN1266150C/zh not_active Expired - Fee Related
- 2002-08-14 CA CA002456349A patent/CA2456349A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1104763A1 (en) * | 1998-08-11 | 2001-06-06 | Sumitomo Pharmaceuticals Company, Limited | Naphthyridine derivatives |
Non-Patent Citations (1)
Title |
---|
See also references of EP1420017A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006011551A1 (ja) * | 2004-07-28 | 2006-02-02 | Sankyo Company Limited | 抗動脈硬化作用を有する医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP1420017A4 (en) | 2004-09-08 |
EP1420017A1 (en) | 2004-05-19 |
AU2002327093B2 (en) | 2007-08-16 |
US7067528B2 (en) | 2006-06-27 |
JP3787139B2 (ja) | 2006-06-21 |
CA2456349A1 (en) | 2003-03-06 |
CN1266150C (zh) | 2006-07-26 |
JPWO2003018581A1 (ja) | 2004-12-09 |
NZ531073A (en) | 2005-09-30 |
CN1545515A (zh) | 2004-11-10 |
US20040116463A1 (en) | 2004-06-17 |
KR20040036724A (ko) | 2004-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1664005B1 (en) | Thiazole derivatives as cannabinoid receptor modulators | |
RU2430099C2 (ru) | Тозилатная соль терапевтического соединения и ее фармацевтические композиции | |
CA2464068C (en) | .alpha.-form or .beta.-form crystal of (r)-2-(2-aminothiazol-4yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl)acetanilide | |
TWI426914B (zh) | Pyrazole derivatives of monoclonal esters | |
ES2208453T3 (es) | Agonistas de los receptores adrenergicos beta 2. | |
BR112020022738A2 (pt) | formas cristalinas de um inibidor tlr7/tlr8 | |
JP2002543075A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
WO2011050742A1 (zh) | 阿戈美拉汀的新晶型及其制备方法 | |
JP2002517385A (ja) | カリウムチャネル阻害剤 | |
JP6203170B2 (ja) | アゴメラチンの新しい結晶形vii、その調製方法及び使用並びにこれを含有する医薬組成物 | |
TW201209041A (en) | New crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide | |
WO2009053840A2 (en) | Solid forms of (±)-o-desmethylvenlafaxine salts | |
BRPI0720793A2 (pt) | SAIS E FORMAS CRISTALINAS DE ÁCIDO 4-[3,5-BIS(2-HIDRÓXI FENIL)-[1,2,4]tRIAZOL-1-IL]BENZOICO | |
CN106045898B (zh) | 一种吲哚类化合物及其制备方法和用途 | |
CA2403264A1 (en) | Chiral fluoroquinolizinone arginine salt forms | |
BR112012027623B1 (pt) | Processo para a produção de sais de ralfinamida metanossulfonato ou seus renantiômeros, forma pseudopolimorfa de hemi-hidrato cristalino h do sal de metanossulfonato de ralfinamida, ou seu r-enantiômero, seu uso e formulação farmacêutica que o compreende | |
US20110014246A1 (en) | Amorphous arformoterol l-(+)-tartrate | |
WO2003018581A1 (fr) | Derive de 1,2-dihydro-2-oxo-1,8-naphthyridine | |
JP2005527518A (ja) | 新規なカルコン(chalcone)誘導体とその使用 | |
JP7453475B2 (ja) | オラパリブシュウ酸共結晶及びその医薬的使用 | |
EP3978476A1 (en) | Solid form of aromatic compound and preparation method therefor | |
JP5042861B2 (ja) | 結晶性1H−イミダゾ[4,5−b]ピリジン−5−アミン,7−[5−[(シクロヘキシルメチルアミノ)−メチル]−1H−インドール−2−イル]−2−メチル,硫酸塩(1:1),三水和物およびその医薬的使用 | |
WO2019200502A1 (zh) | 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物 | |
WO2006121151A1 (ja) | 1-メチルカルバペネム化合物の結晶 | |
CA2421499A1 (en) | Novel crystals of 1,3,4-oxadiazole derivative, process for producing the same and pharmaceutical agent containing the same as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2003523242 Country of ref document: JP Kind code of ref document: A |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10474725 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2456349 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002327093 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002760629 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 531073 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047002489 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028164431 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002760629 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 531073 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 531073 Country of ref document: NZ |